Bicara Therapeutics (NASDAQ:BCAX) Shares Up 6.7% – Still a Buy?

Bicara Therapeutics Inc. (NASDAQ:BCAX)’s share price shot up 6.7% on Friday . The stock traded as high as $13.17 and last traded at $13.19. 129,790 shares changed hands during mid-day trading, a decline of 64% from the average session volume of 362,154 shares. The stock had previously closed at $12.36.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on BCAX. Rodman & Renshaw began coverage on shares of Bicara Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 target price for the company. HC Wainwright lifted their target price on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a report on Monday, January 27th. Wedbush reiterated an “outperform” rating and issued a $31.00 target price on shares of Bicara Therapeutics in a report on Wednesday, February 12th. Finally, RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $41.20.

Bicara Therapeutics Trading Up 7.6 %

The firm has a 50 day simple moving average of $13.94.

Institutional Investors Weigh In On Bicara Therapeutics

Several institutional investors have recently modified their holdings of the company. Spire Wealth Management purchased a new stake in shares of Bicara Therapeutics during the 4th quarter worth $31,000. BNP Paribas Financial Markets purchased a new stake in shares of Bicara Therapeutics during the 4th quarter worth $32,000. Legal & General Group Plc purchased a new stake in shares of Bicara Therapeutics during the 4th quarter worth $33,000. Summit Investment Advisors Inc. purchased a new stake in shares of Bicara Therapeutics during the 4th quarter worth $35,000. Finally, Virtus ETF Advisers LLC purchased a new stake in shares of Bicara Therapeutics during the 4th quarter worth $69,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.